What's in Mohammed Milhem, MBBS's pipeline?

Mohammed Milhem, MBBS has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Mohammed Milhem, MBBS's portfolio?

Top competitors by shared drug class: , Abramson Cancer Center at Penn Medicine, Eli Lilly, Heather Wakelee, Merck And Co Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mohammed-milhem-mbbs.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Mohammed Milhem, MBBS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mohammed Milhem, MBBS pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ascorbate	Ascorbate	marketed	Vitamin D [EPC]		Other

Therapeutic area mix

Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Abramson Cancer Center at Penn Medicine · 1 shared drug class
Eli Lilly · 1 shared drug class
Heather Wakelee · 1 shared drug class
Merck And Co Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mohammed Milhem, MBBS:

Cite this brief

Drug Landscape (2026). Mohammed Milhem, MBBS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mohammed-milhem-mbbs. Accessed 2026-06-10.